Brief: Bayer AG Says Phase II Aracog Head-To-Head Trial Met Its Primary Endpoint
30/05/2026 22:27
BRIEF-Bayer AG Says Phase II Aracog Head-To-Head Trial Met Its Primary Endpoint May 30 (Reuters) - Bayer AG BAYGn.DE:
BAYER AG - PHASE II ARACOG (AFT-47) HEAD-TO-HEAD TRIAL MET ITS PRIMARY ENDPOINT
BAYER AG - PATIENTS TREATED WITH NUBEQA(®) (DAROLUTAMIDE) SHOWED A DECLINE IN MAXIMALLY CHANGED COGNITIVE DOMAIN (MCCD) BY 24 WEEKS
Source text: ID:nBwbgnJSQa
Further company coverage: [BAYGn.DE]
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bayer AG
See all newsBrief: Bayer Says Finerenone Slowed Kidney Decline In CKD
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant
Deutsche Bank AG FF - Post Stabilisation Notice -Bayer EUR 30NC6 & 30NC9
Brief: Bayer To Present New Finerenone Data Across Chronic Kidney Disease With And Without Diabetes At Asn Kidney Week 2026
Brief: FDA Approves Once-Weekly Generic Hormone Therapy Patch For Women